OPKO Health, Inc. (NASDAQ: OPK) Q2 2026 Earnings Preview: Key Financials and Valuation Insights

• OPKO Health anticipates a negative EPS of -$0.08 and revenue of $131.23 million for Q2 2026, reflecting recent profitability challenges.
• Despite profitability issues, OPKO Health maintains a healthy balance sheet with a debt-to-equity ratio of 0.33 and a strong current ratio of 3.61.

OPKO Health, Inc. (NASDAQ: OPK) is a fully-integrated healthcare company. The company announced it will report its second-quarter 2026 financial results on Monday, July 27, 2026, after the market closes. Following the release, senior management will host a conference call to discuss the results and provide a business update, offering crucial investment insights.

For the upcoming report, Wall Street analysts are estimating an earnings per share (EPS) of -$0.08. EPS represents the company's profit allocated to each share of stock. Analysts also project revenue of approximately $131.23 million for the quarter, providing key profitability metrics.

The negative EPS estimate aligns with OPKO Health's recent stock performance. Over the last twelve months, the company has a negative price-to-earnings (P/E) ratio of -4.43, which indicates it was not profitable during that period. This is further reflected in its negative earnings yield of approximately -23.00%, crucial for financial analysis.

From a valuation perspective, OPKO Health's price-to-sales ratio is 1.59. This ratio compares the company's stock price to its revenues. The enterprise value-to-operating cash flow ratio is -5.98, which suggests the company has a negative cash flow from its core business operations, impacting investment metrics.

In terms of financial health, OPKO Health has a debt-to-equity ratio of 0.33, showing it has less debt relative to its shareholder equity. The company also has a strong current ratio of 3.61. This indicates a solid ability to meet its short-term financial obligations, vital for balance sheet analysis.